Introduction: We reported the mortality and morbidity of patients, over 85-year old, with cardiac
diseases in our institution. Long term use of Tolvaptan improved the rate of readmission.
Methods and Results: From October/2016 to May/2017, forty-three patients with cardiac diseases admitted
in our institution. Thirty-one patients discharged and Tolvaptan (3.75 mg or 7.5 mg)
was continuously used for 22 among 31 patients after discharge. First re-admission
was observed in 13 patients. By Kaplan-Meier method, the mortality and first re-admission
rate due to all causes were 70%, but competitive risk with cardiac mortality was 15%,
non-cardiac mortality was 7.5%, cardiac re-admission was 13% and non-cardiac re-admission
was 33%. Conclusion: Cardiac events induced to the high rate of mortality, but long term use of Tolvaptan
reduced re-admission with cardiac events.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Cardiac FailureAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
